Key Inclusion Criteria:~* Aged 50 to 89 (inclusive) at screening~* Mild Cognitive Impairment (MCI) due to AD or
Mild dementia due to AD according to workgroups of the Diagnostic Guidelines of the National Institute on Aging
and Alzheimer's Association (NIA-AA)~* Mini-Mental State Examination (MMSE) score 20-30 inclusive at
screening-. Montreal Cognitive Assessment score (MoCA) < 26 at screening~* Clinical Dementia Rating (CDR)
global score of 0.5 or 1 with memory score of greater or equal to 0.5 at screening~* Positive plasma AD
biomarker signature~* Participants who are treated with FDA-approved acetylcholinesterase inhibitors
(AchEI)and/or memantine will have to be on a stable dosage regimen for at least 3 months prior to screening.~*
Participants must have a study partner who has frequent interaction with them (approximately >3-4 times per
week), will be available for all clinic visits in person or remotely, and can assist in compliance with study
procedures.~* Female participants must be post-menopausal for at least one year or surgically sterile(bilateral
tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.~* Fluent in
English or Spanish to ensure compliance with cognitive testing and study visit procedures.~* Ambulatory, or
able to walk with an assistive device.~* Provision of informed consent from the participant (or the
participant's legally authorized representative (LAR) if unable to provide consent) and the study partner.~Key
